216 related articles for article (PubMed ID: 21239698)
21. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol.
Shah MA; Kortmansky J; Motwani M; Drobnjak M; Gonen M; Yi S; Weyerbacher A; Cordon-Cardo C; Lefkowitz R; Brenner B; O'Reilly E; Saltz L; Tong W; Kelsen DP; Schwartz GK
Clin Cancer Res; 2005 May; 11(10):3836-45. PubMed ID: 15897584
[TBL] [Abstract][Full Text] [Related]
22. [Mitoxantrone and conventional-dose cytosine arabinoside for relapsed and refractory acute leukemia].
Wakita A; Murase T; Uchida T; Fujiwara Y; Tanaka M; Ohkita T
Gan To Kagaku Ryoho; 1992 May; 19(5):653-7. PubMed ID: 1580638
[TBL] [Abstract][Full Text] [Related]
23. Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer.
Tan AR; Yang X; Berman A; Zhai S; Sparreboom A; Parr AL; Chow C; Brahim JS; Steinberg SM; Figg WD; Swain SM
Clin Cancer Res; 2004 Aug; 10(15):5038-47. PubMed ID: 15297405
[TBL] [Abstract][Full Text] [Related]
24. Mitoxantrone and continuous infusion of cytosine arabinoside in refractory and relapsed acute lymphoblastic leukemia.
Liso V; Specchia G; Capalbo S; Pavone V; Iacobazzi A; Iaculli ML; Dione R; Pansini N
Acta Haematol; 1992; 87(1-2):54-7. PubMed ID: 1585771
[TBL] [Abstract][Full Text] [Related]
25. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.
Karp JE; Thomas BM; Greer JM; Sorge C; Gore SD; Pratz KW; Smith BD; Flatten KS; Peterson K; Schneider P; Mackey K; Freshwater T; Levis MJ; McDevitt MA; Carraway HE; Gladstone DE; Showel MM; Loechner S; Parry DA; Horowitz JA; Isaacs R; Kaufmann SH
Clin Cancer Res; 2012 Dec; 18(24):6723-31. PubMed ID: 23092873
[TBL] [Abstract][Full Text] [Related]
26. A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.
Holkova B; Supko JG; Ames MM; Reid JM; Shapiro GI; Perkins EB; Ramakrishnan V; Tombes MB; Honeycutt C; McGovern RM; Kmieciak M; Shrader E; Wellons MD; Sankala H; Doyle A; Wright J; Roberts JD; Grant S
Clin Cancer Res; 2013 Apr; 19(7):1873-83. PubMed ID: 23515411
[TBL] [Abstract][Full Text] [Related]
27. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
Thiel A; Schetelig J; Pönisch W; Schäfer-Eckart K; Aulitzky W; Peter N; Schulze A; Maschmeyer G; Neugebauer S; Herbst R; Hänel A; Morgner A; Kroschinsky F; Bornhäuser M; Lange T; Wilhelm M; Niederwieser D; Ehninger G; Fiedler F; Hänel M; ;
Ann Oncol; 2015 Jul; 26(7):1434-40. PubMed ID: 25922062
[TBL] [Abstract][Full Text] [Related]
28. A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.
Ramaswamy B; Phelps MA; Baiocchi R; Bekaii-Saab T; Ni W; Lai JP; Wolfson A; Lustberg ME; Wei L; Wilkins D; Campbell A; Arbogast D; Doyle A; Byrd JC; Grever MR; Shah MH
Invest New Drugs; 2012 Apr; 30(2):629-38. PubMed ID: 20938713
[TBL] [Abstract][Full Text] [Related]
29. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol.
Thomas JP; Tutsch KD; Cleary JF; Bailey HH; Arzoomanian R; Alberti D; Simon K; Feierabend C; Binger K; Marnocha R; Dresen A; Wilding G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):465-72. PubMed ID: 12451473
[TBL] [Abstract][Full Text] [Related]
30. Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.
Holkova B; Kmieciak M; Perkins EB; Bose P; Baz RC; Roodman GD; Stuart RK; Ramakrishnan V; Wan W; Peer CJ; Dawson J; Kang L; Honeycutt C; Tombes MB; Shrader E; Weir-Wiggins C; Wellons M; Sankala H; Hogan KT; Colevas AD; Doyle LA; Figg WD; Coppola D; Roberts JD; Sullivan D; Grant S
Clin Cancer Res; 2014 Nov; 20(22):5652-62. PubMed ID: 25248382
[TBL] [Abstract][Full Text] [Related]
31. Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).
Maddocks K; Wei L; Rozewski D; Jiang Y; Zhao Y; Adusumilli M; Pierceall WE; Doykin C; Cardone MH; Jones JA; Flynn J; Andritsos LA; Grever MR; Byrd JC; Johnson AJ; Phelps MA; Blum KA
Am J Hematol; 2015 Apr; 90(4):327-33. PubMed ID: 25639448
[TBL] [Abstract][Full Text] [Related]
32. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
Senderowicz AM; Headlee D; Stinson SF; Lush RM; Kalil N; Villalba L; Hill K; Steinberg SM; Figg WD; Tompkins A; Arbuck SG; Sausville EA
J Clin Oncol; 1998 Sep; 16(9):2986-99. PubMed ID: 9738567
[TBL] [Abstract][Full Text] [Related]
33. Intensive consolidation chemotherapy for newly diagnosed acute myeloid leukemia using a regime containing moderate dose cytosine arabinoside and mitoxantrone.
Liang R; Chan TK; Chu YC; Chan J; Chan CH; Chiu E; Lie A; Kwong YL; Yeung YM; Chan LC
Anticancer Drugs; 1995 Apr; 6(2):224-8. PubMed ID: 7795271
[TBL] [Abstract][Full Text] [Related]
34. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.
Phelps MA; Lin TS; Johnson AJ; Hurh E; Rozewski DM; Farley KL; Wu D; Blum KA; Fischer B; Mitchell SM; Moran ME; Brooker-McEldowney M; Heerema NA; Jarjoura D; Schaaf LJ; Byrd JC; Grever MR; Dalton JT
Blood; 2009 Mar; 113(12):2637-45. PubMed ID: 18981292
[TBL] [Abstract][Full Text] [Related]
35. Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia.
Rizzieri DA; Bass AJ; Rosner GL; Gockerman JP; DeCastro CM; Petros WP; Adams DJ; Laughlin MJ; Davis P; Foster T; Jacobson R; Hurwitz H; Moore JO
J Clin Oncol; 2002 Feb; 20(3):674-9. PubMed ID: 11821447
[TBL] [Abstract][Full Text] [Related]
36. Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia.
Zeidner JF; Karp JE
Leuk Res; 2015 Dec; 39(12):1312-8. PubMed ID: 26521988
[TBL] [Abstract][Full Text] [Related]
37. Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.
Ozkaynak MF; Avramis VI; Carcich S; Ortega JA
Med Pediatr Oncol; 1998 Dec; 31(6):475-82. PubMed ID: 9835899
[TBL] [Abstract][Full Text] [Related]
38. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.
Hänel M; Friedrichsen K; Hänel A; Herbst R; Morgner A; Neser S; Nicklisch M; Teich M; Ehninger G; Fiedler F
Onkologie; 2001 Aug; 24(4):356-60. PubMed ID: 11574763
[TBL] [Abstract][Full Text] [Related]
39. Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia.
Visani G; Milligan D; Leoni F; Chang J; Kelsey S; Marcus R; Powles R; Schey S; Covelli A; Isidori A; Litchman M; Piccaluga PP; Mayer H; Malagola M; Pfister C
Leukemia; 2001 May; 15(5):764-71. PubMed ID: 11368437
[TBL] [Abstract][Full Text] [Related]
40. Flavopiridol in the treatment of chronic lymphocytic leukemia.
Christian BA; Grever MR; Byrd JC; Lin TS
Curr Opin Oncol; 2007 Nov; 19(6):573-8. PubMed ID: 17906454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
